Department of Cardiology, University Hospitals Leuven, Leuven, Belgium.
Department of Nuclear Medicine, University Hospitals Leuven, Leuven, Belgium.
Acta Cardiol. 2022 Dec;77(10):900-909. doi: 10.1080/00015385.2022.2040823. Epub 2022 Feb 17.
F-FDG PET/CT is a valuable diagnostic tool in infective endocarditis (IE). However, the prognostic value is unclear. This study aims to evaluate the prognostic performance of F-FDG PET/CT in native valve endocarditis (NVE) and prosthetic valve endocarditis (PVE).
We retrospectively included 76 patients treated for definite IE (NVE and PVE) that underwent F-FDG PET/CT between January 2016 and December 2018. Clinical, echocardiographic and F-FDG PET/CT (pathologic valvular F-FDG uptake, extracardiac complications (ECC)) data were collected. The primary endpoint was defined as mortality or recurrence of IE at a one-year follow-up.
Pathologic valvular F-FDG uptake was detected in 32 of 57 (56.1%) patients, 30% (9/30) in NVE and 85.2% (23/27) in PVE group. Atrial fibrillation (OR 3.90, 95% CI = 1.14-16.3), prior anticoagulation treatment (OR 6.37, 95% CI = 1.89-26.7), large vegetation (≥ 10 mm) (OR 4.05, 95% CI = 1.14-16.1), perivalvular complications (OR 7.22, 95% CI = 1.68-55.1) and abscess (OR 10.9, 95% CI = 1.84-283) were associated with positive PET/CT. Extracardiac complications were found in 27 of 76 (35.5%) patients, 42.9% (18/42) in the NVE and 26.5% (9/34) in the PVE group. Pathological valvular tracer uptake (HR 1.20, 95% CI = 0.43-3.37) or extracardiac complications (HR 0.58, 95% CI = 0.21-1.62) were not associated with the occurrence of the primary endpoint.
Our study could not demonstrate a prognostic value of F-FDG PET/CT in IE, but confirms high diagnostic performance, which may compromise prognostic significance by accelerated optimal treatment because of earlier diagnostic certainty.
18F-氟脱氧葡萄糖正电子发射断层扫描/计算机断层扫描(18F-FDG PET/CT)在感染性心内膜炎(IE)中是一种有价值的诊断工具。然而,其预后价值尚不清楚。本研究旨在评估 18F-FDG PET/CT 在原发性心内膜炎(NVE)和人工瓣膜心内膜炎(PVE)中的预后价值。
我们回顾性纳入了 2016 年 1 月至 2018 年 12 月期间因明确的 IE(NVE 和 PVE)而接受 18F-FDG PET/CT 检查的 76 例患者。收集了临床、超声心动图和 18F-FDG PET/CT(病理性瓣膜 18F-FDG 摄取、心外并发症(ECC))数据。主要终点定义为一年随访时的死亡率或 IE 复发。
57 例患者中有 32 例(56.1%)检测到病理性瓣膜 18F-FDG 摄取,NVE 组为 30%(9/30),PVE 组为 85.2%(23/27)。心房颤动(OR 3.90,95%CI=1.14-16.3)、既往抗凝治疗(OR 6.37,95%CI=1.89-26.7)、大的赘生物(≥10mm)(OR 4.05,95%CI=1.14-16.1)、瓣周并发症(OR 7.22,95%CI=1.68-55.1)和脓肿(OR 10.9,95%CI=1.84-283)与阳性 PET/CT 相关。76 例患者中有 27 例(35.5%)发现心外并发症,NVE 组为 42.9%(18/42),PVE 组为 26.5%(9/34)。病理性瓣膜示踪剂摄取(HR 1.20,95%CI=0.43-3.37)或心外并发症(HR 0.58,95%CI=0.21-1.62)与主要终点的发生无关。
本研究未能证明 18F-FDG PET/CT 在 IE 中的预后价值,但证实了其具有较高的诊断性能,这可能由于早期诊断的确定性而加速了最佳治疗,从而影响了预后的意义。